Introduction: In developing countries, patients tend to present late to healthcare facilities and this makes early diagnosis impossible. The experience among patients with haematologic malignancies in our part of the world is not different. The objective of this survey was to ide...
Open access
Research Article10.9734/ibrr/2025/v16i4373
Introduction: Chemotherapy regimens used in treating haematologic malignancies could be targeted or non-specific. Targeted-therapy requires further confirmatory testing to be done and these could occasion delays in initiation. Cost of regimens and availability of these regimens a...
Open access
Research Article10.9734/ijr2h/2025/v8i2186
Paxman Dandyson Uku, Emmanuel Wobo, Christine Abaiayam Dangana, Amarachi Faith Mbonu, Blessing Edna Amuah, Ayomide Wachuku, Doreen Obugheni Arugu & Chimankpam Edison Okechukwu Omeodu·Journal of Cancer and Tumor International·2025
Background: Treatment of haematologic malignancies with chemotherapy is associated with side effects. Chemotherapy-induced thrombocytopaenia, a recognized side effect, have been defined by nadir platelet counts, at different cycles of chemotherapy. A lot more studies describe thi...
Open access
Research Article10.9734/jcti/2025/v15i4319